Collagenase Clostridium Histolyticum In Peyronie'S Disease: Introduction Of This Novel Treatment In The Netherlands

In this research patients with Peyronie's disease (PD) were treated with Collagenase Clostridium Histolyticum (CCH) which is the only medicine registered for treatment of PD. We present the results of the first patients treated in The Netherlands according to the original scheme. From 1-1-2018 to 1-7-2018 twelve patients were included following the Impress 1&2 studies. Every 6 weeks, 2 injections of 0.9 mg CCH into the nodule in the penis, at intervals of 48-72 hours between the injections (4x2 injections). This was combined with bending and stretching of the penis during the weeks where no injection was given. Primary results included reduction of curvature and being able to perform Coitus. Secondary results are complications (Clavien); pain with the injection and Patient Reported Outcome Measurements (PROM). Nine patients (75%) completed treatment of 4x2 injections. Three patients dropped out after 2x2 doses, due to pain, showing no effect on the curvature and providing no photograph. Mean improvement of the curvature was 18 degrees (-4 to 49; 27%). Sexual intercourse was possible in six patients (50%). The mean reported pain score from each injection was 3.7 (0-8, N=63) on a scale from 0-10. The reported satisfaction was 6.9 (scale 0-10). When asked, all patients who finished the treatment (N=9) would recommend the treatment. Seven patients felt improvement in sexual intercourse. One patient developed an infection which required antibiotic treatment (Clavien 2). Other patients developed hematoma in the penis (Clavien 1)